Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen stock has had a difficult few weeks, with the stock dropping from 295 to 240. It is currently the most oversold stock in the Dow Jones Industrial Average.

How To Profit From Amgen Stock's Plunge Using Options

Amgen's share price has dropped by a material amount over the past couple of months. It maintains solid profitability and has a burgeoning portfolio of biosimilars, including its answer to HUMIRA.

Amgen: Price Crash Spells Opportunity

Exact Sciences

Gilead Sciences

GlaxoSmithKline

Immunocore Holdings

Eli Lilly

Moderna

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.

Is Biotech Immunocore About To Make A 25% Price Move?

Apple

Boeing

Salesforce

Cisco Systems

Chevron

Disney

Dow Inc

Intel

JPMorgan Chase & Co

Coca-Cola

Microsoft

UnitedHealth Group

Verizon

Walgreens

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.” – Dow Jones & Co. The highest-yield 10 are February's Dogs of the Dow: KO, CSCO, AMGN, CVX, DOW, IBM, INTC, MMM, WBA, and VZ, averaging a 4.41% annual yield.

Buy 3 February Dogs Of The Dow, Watch 2 More

AstraZeneca

1Life Healthcare

Pfizer

Third Harmonic Bio Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That May Rally - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)

Johnson & Johnson

The blue-chip index is up just 2.7% year to date, behind the S&P 500's 8.9% gain

What's Ailing the Dow This Year? UnitedHealth, Chevron, J&J, Amgen.

Goldman Sachs

Merck

While investing in the new normal seemingly focused on meme trades and other high-risk ventures, targeting the companies of the Dow Jones is always relevant, particularly if they're among the most undervalued Dow stocks to buy. Granted, this venerable list doesn't bring much excitement.

The 7 Most Undervalued Dow Stocks to Buy in February 2023

Now Offers Patients the Choice of Administration at Home or in a Doctor's Office THOUSAND OAKS, Calif. , Feb. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.1 First approved by the FDA in December 2021, TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g.

TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN

Advanced Micro Devices

Electronic Arts

FedEx

Peloton

Rivian Automotive

Snap

Stryker

U.S. stock markets started Feb. 1 with declines on news of the Fed's latest rate hike but ended the day higher following comments from the Fed chair.

US Markets Rally Back on Powell Comments

The company's latest quarter wasn't its most impressive.

Why Amgen Stock Wilted on Wednesday

Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.

Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics

Amgen Inc. (NASDAQ:AMGN ) Q4 2022 Earnings Conference Call January 31, 2023 4:30 PM ET Company Participants Arvind Sood - Vice President of Investor Relations Bob Bradway - Chairman & Chief Executive Officer Murdo Gordon - Executive Vice President of Global Commercial Operations David Reese - Executive Vice President of R&D Peter Griffith - Chief Financial Officer Conference Call Participants Operator My name is Jason, and I will be the conference facilitator today for Amgen's Fourth Quarter Full Year 2022 Financial Results Conference Call. [Operator Instructions] I would now like to introduce Mr.

Amgen Inc. (AMGN) Q4 2022 Earnings Call Transcript

THOUSAND OAKS, Calif. , Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN)  posted the full transcript and audio replay of the company's 2022 fourth quarter and full year financial results webcast from earlier today.

AMGEN POSTS FULL TRANSCRIPT AND AUDIO REPLAY OF FOURTH QUARTER AND FULL YEAR 2022 EARNINGS WEBCAST

Amgen (AMGN) delivered earnings and revenue surprises of 1.24% and 1.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Surpasses Q4 Earnings and Revenue Estimates

Alcoa

Bank of America

Blackstone Group

Coca-Cola European Partners plc

Comcast

Delta Air Lines

Emerson Electric

Glencore PLC

Medtronic

Madison Square Garden Sports

Orange

Paramount Global

PNC Financial Services

Porsche Automobil Holding SE

Prudential Financial

Repsol SA

Roche Holding AG

Raytheon Technologies

Sysco

Two Barron's Annual Roundtable, plus one Bloomberg Intelligence articles published late-January listed 99 intriguing stocks for 2023; 77 were unduplicated US publicly-listed companies, of which, 56 paid-dividends. Barron's two roundtable discussions January 20 and 27 split 49 picks from 9 panelists in half, whereas Bloomberg detailed all 50 in their January 16 BusinessWeek edition.

Barron's And Bloomberg 2023 Ideal Dividend Stocks Of The Year

Amgen Inc. topped Wall Street expectations for its fourth quarter, but the drug maker's shares fell after hours as its 2023 guidance fell on the lower end of Wall Street's expectations.

Amgen's Q4 tops views, but 2023 guidance falls on lower end of expectations

Amgen stock dipped late Tuesday after fourth-quarter earnings missed expectations, though sales came in narrowly above. The post Amgen Sinks On Mixed Earnings As 2023 Guidance Comes Up Short appeared first on Investor's Business Daily.

Amgen Sinks On Mixed Earnings As 2023 Guidance Comes Up Short

Amgen Inc on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co.

Amgen revenue falls slightly as Lilly COVID deal contributes less

AMGEN ALSO PROVIDES 2023 GUIDANCE EXCLUDING ANY CONTRIBUTION FROM THE ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS THOUSAND OAKS, Calif. , Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021.

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

AbbVie

AbbVie's two-decade Humira monopoly came to an end Tuesday after Amgen launched its biosimilar copy. But AbbVie stock was mostly unmoved.

AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff

News for Amgen Stock (AMGN)